Dianicline information

Dianicline
Clinical data
ATC code	none;
Identifiers
	IUPAC name (5aS,8S,10aR)-5a,6,9,10-Tetrahydro,7H,11H-8,10a-methanopyrido[2',3':5,6]pyrano[2,3-d]azepine;
CAS Number	292634-27-6 ;
PubChem CID	9816447;
ChemSpider	8352269 ;
UNII	Y0SNM34C6O;
ChEMBL	ChEMBL187927 ;
CompTox Dashboard (EPA)	DTXSID30870314 ;
Chemical and physical data
Formula	C13H16N2O
Molar mass	216.284 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1CN2CC[C@@]3(C2)[C@H]1OC4=C(C3)N=CC=C4;
	InChI InChI=1S/C13H16N2O/c1-2-11-10(14-5-1)8-13-4-7-15(9-13)6-3-12(13)16-11/h1-2,5,12H,3-4,6-9H2/t12-,13+/m0/s1 ; Key:SUPRUPHAEXPGPF-QWHCGFSZSA-N ;
	(what is this?) (verify)

Dianicline (SSR-591,813) is a drug developed by Sanofi-Aventis which acts as a partial agonist at neural nicotinic acetylcholine receptors. It is subtype-selective, binding primarily to the α4β2 subtype. It is being developed as a medication for the treatment of nicotine dependence to assist in smoking cessation.^[1] Dianicline is very similar to the already marketed drug varenicline and it is unclear what advantages it will have over the older drug, although it may have an improved side effect profile. It has been through human trials up to Phase II, although results have not yet been reported. Drug development has been discontinued after reporting of unfavourable results during Phase III trials.^[2]^[3]^[4]

^ Cohen C, Bergis OE, Galli F, Lochead AW, Jegham S, Biton B, et al. (July 2003). "SSR591813, a novel selective and partial alpha4beta2 nicotinic receptor agonist with potential as an aid to smoking cessation". The Journal of Pharmacology and Experimental Therapeutics. 306 (1): 407–20. doi:10.1124/jpet.103.049262. PMID 12682217. S2CID 37543790.
^ Fagerström K, Balfour DJK. Neuropharmacology and potential efficacy of new treatments for tobacco dependence. Expert Opinion on Investigational Drugs. 2006; 15(2):107-116.
^ Efficacy and Safety of Dianicline Versus Placebo as an Aid to Smoking Cessation
^ "Sanofi Pipeline" (PDF). Archived from the original (PDF) on 2008-12-04. Retrieved 2009-06-24.

[1] Cohen C, Bergis OE, Galli F, Lochead AW, Jegham S, Biton B, et al. (July 2003). "SSR591813, a novel selective and partial alpha4beta2 nicotinic receptor agonist with potential as an aid to smoking cessation". The Journal of Pharmacology and Experimental Therapeutics. 306 (1): 407–20. doi:10.1124/jpet.103.049262. PMID 12682217. S2CID 37543790.

[2] Fagerström K, Balfour DJK. Neuropharmacology and potential efficacy of new treatments for tobacco dependence. Expert Opinion on Investigational Drugs. 2006; 15(2):107-116.

[3] Efficacy and Safety of Dianicline Versus Placebo as an Aid to Smoking Cessation

[4] "Sanofi Pipeline" (PDF). Archived from the original (PDF) on 2008-12-04. Retrieved 2009-06-24.

Dianicline information

and 24 Related for: Dianicline information

Dianicline

Cocaine

Methamphetamine

Nitrous oxide

Caffeine

Tobacco

Pentobarbital

Xenon

Ivermectin

Modafinil

Adderall

Crack cocaine

Bupropion

Anticholinergic

Progesterone

Mephedrone

Dextromethorphan

Datura

Barbiturate

Phencyclidine

Glycerophosphorylcholine

MDMA

Pantothenic acid

Psychoactive drug

Clinical data


ATC code	none
Identifiers
IUPAC name (5aS,8S,10aR)-5a,6,9,10-Tetrahydro,7H,11H-8,10a-methanopyrido[2',3':5,6]pyrano[2,3-d]azepine
CAS Number	292634-27-6^Y
PubChem CID	9816447
ChemSpider	8352269^N
UNII	Y0SNM34C6O
ChEMBL	ChEMBL187927^N
CompTox Dashboard (EPA)	DTXSID30870314
Chemical and physical data
Formula	C₁₃H₁₆N₂O
Molar mass	216.284 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES C1CN2CC[C@@]3(C2)[C@H]1OC4=C(C3)N=CC=C4
InChI InChI=1S/C13H16N2O/c1-2-11-10(14-5-1)8-13-4-7-15(9-13)6-3-12(13)16-11/h1-2,5,12H,3-4,6-9H2/t12-,13+/m0/s1^N Key:SUPRUPHAEXPGPF-QWHCGFSZSA-N^N
^NY (what is this?) (verify)